Form 4 Filing for Cellectar Biosciences, Inc. - Officer/Director Stock Option Grant

This filing details a Form 4 submission for Cellectar Biosciences, Inc. (CLRB), reporting the grant of stock options to Frederick Driscoll, a director. On July 7, 2026, Mr. Driscoll was granted 25,000 stock options for the company's common stock at a price of $0.00 per share. These options are set to vest in full on July 7, 2027, contingent upon his continued service. The options have an exercise price of $2.70 and an expiration date of July 7, 2036. The transaction is classified as direct ownership, with the acquisition code indicating a grant. The filing was signed on July 8, 2026, by Chad Kolean as attorney-in-fact for Mr. Driscoll.